23andme Holding Co  (ME)
Other Ticker:  
Price: $0.8956 $0.03 2.883%
Day's High: $0.9365 Week Perf: 1.89 %
Day's Low: $ 0.85 30 Day Perf: 15.98 %
Volume (M): 2,945 52 Wk High: $ 3.48
Volume (M$): $ 2,638 52 Wk Avg: $1.81
Open: $0.90 52 Wk Low: $0.61

 Market Capitalization (Millions $) 425
 Shares Outstanding (Millions) 475
 Employees 700
 Revenues (TTM) (Millions $) 270
 Net Income (TTM) (Millions $) -336
 Cash Flow (TTM) (Millions $) -155
 Capital Exp. (TTM) (Millions $) 12

23andme Holding Co
The company known as 23andMe Holding Co., previously named VG Acquisition Corp., is dedicated to assisting individuals in living healthier lives. Their goal is to help people access, comprehend and benefit from the human genome. They believe that their extensive database of genetic and phenotypic information can revolutionize healthcare. They obtain this data from millions of customers who separately consent to participate in their research. The company is committed to ethical, scientific, and privacy standards to provide trustworthy health and genetic information.

23andMe Holding Co. was the first to provide direct-to-consumer genetic testing, allowing individuals to have access to unique, personalized genetic health risks, ancestry, and traits. The company has multiple Food and Drug Administration ("FDA") authorizations for over-the-counter health and carrier status reports. 23andMe Holding Co. is the only company to obtain FDA authorization for all carrier status, genetic health risk, cancer predisposition, and pharmacogenetics reports. Customers can choose from over 60 health reports in the U.S.

In November 2021, 23andMe Holding Co. acquired Lemonaid Health, Inc., making personalized healthcare accessible for all. Lemonaid offers affordable and direct online access to medical care, from consultation through treatment, for a variety of common conditions, using evidence-based guidelines and clinical protocols to provide quality patient care. Patients can use the online pharmacy for fast and free delivery when prescribed medication by medical professionals.

The company operates in two reporting segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment includes the Personal Genome Service' ('PGS'), telehealth services, and research services. The PGS service provides customers with genetic reports on ancestral origins, personal genetic health risks, and the chances of passing on rare carrier conditions to their children. Customers can access PGS services on the website, 23andMe.com, or mobile app. Customers can upgrade from the Ancestry + Traits Service to the Health + Ancestry Service for a fee. 23andMe+ premium subscription service offers customers the Health + Ancestry Service, pharmacogenetic reports, personalized genetic risk reports, and advanced ancestry and health features. The company's research programs allow customers to participate voluntarily. 80% of customers have participated in the programs. The company analyzes the data provided by the customers and uses proprietary machine learning techniques to gain insight into how genetic variants affect the likelihood of individuals developing specific diseases.

The telehealth segment provides patients with medical consultation and treatment from one of their affiliated licensed physicians or nurse practitioners via telehealth. Patients can access the online pharmacy for fast and free delivery of non-controlled medications for acute and chronic conditions at affordable prices. The Consumer & Research Services segment accounts for the majority of the company's revenue.

   Company Address: 349 Oyster Point Boulevard South San Francisco, 94080 CA
   Company Phone Number: 938-6300   Stock Exchange / Ticker: NASDAQ ME
   ME is expected to report next financial results on February 07, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Evofem Biosciences Inc

Serious revenue fall, at Evofem Biosciences Inc in the fiscal third quarter of 2023

For the third quarter of 2023 Evofem Biosciences Inc had turn a round to earnings by posting EPS of $0.10 per share compare to $-0.04 a year prior and net profit per share turned positive from $-5.43 per share from the preceding financial reporting period. The revenue declined widely by -19.761 % to $5.11 million from $6.37 million in the corresponding financial reporting period a year prior and sequentially Revenue doubled by 107.974 % from $2.46 million.

Shuttle Pharmaceuticals Holdings Inc

Shuttle Pharmaceuticals Holdings Inc. Faces a Bumpy Ride: Operating Results Decline in Recent Fiscal Period for Major Pharmaceutical Preparations Company

In the dynamic and ever-evolving world of the stock market, there are always exciting new opportunities waiting to be discovered. While the major players in the pharmaceutical industry tend to grab most of the headlines, it is often the lesser-known companies that can offer hidden gems for astute investors. One such company, Shuttle Pharmaceuticals Holdings Inc (SHPH), has recently published its financial report for the third quarter of 2023, shedding light on its performance and potential for growth.
Despite reporting an operating loss of $-1.599146 million for the third quarter of 2023, SHPH has displayed a promising upward trajectory. Although the company has not released its top-line figures yet, it is essential to consider its previous accomplishments to put its recent performance into context. In the third quarter of 2022, SHPH recorded an operating loss of $-0.821468 million, indicating significant progress within just one year.

Cingulate Inc

The company declared operating shortfall in the third quarter of 2023

Bearish Sentiment Surrounding Cingulate Inc: A Closer Look at the Financials
Cingulate Inc, a Kansas City-based biopharmaceutical company operating in the Major Pharmaceutical Preparations sector, recently reported an operating shortfall of $-5.749674 million for the third quarter of 2023. This is a significant decrease when compared to the operating shortfall of $-3.968362 million reported in the same quarter of the previous year.
This decline in financial performance is a cause for concern. While companies in the pharmaceutical industry often experience fluctuations in revenue and profitability due to the challenges of developing innovative drugs, Cingulate Inc's consistent downward trend in operating shortfall is worrisome.
The management of Cingulate Inc aims to develop lucrative revenue sources by utilizing their proprietary Precision Timed Release (PTR) drug delivery platform technology. However, the results for the third quarter of 2023 indicate that these efforts have not yet yielded positive outcomes. The operating shortfall soared to $-5.979 million, indicating that the company's attempts to generate revenue have not been successful.

Harrow Inc

Harrow Inc Achieves Remarkable 49.84% Top-line Surge during Exceptional Q3 2023 Earnings Season

As the Chief Financial Correspondent at The , I would like to delve into the financial results of Harrow Inc for the fiscal period ending September 30, 2023. These results tell a story of progress and resilience in a volatile market. Despite recent decline in share values, Harrow Inc's steady financial improvement and increased revenue demonstrate its ability to navigate challenging times.
Profitability and Earnings:
Harrow Inc has made substantial progress in terms of earnings per share (EPS). In the fiscal year ending September 30, 2023, the company reduced its loss per share from $-0.24 to $-0.13. This represents a significant improvement in profitability, reflecting the company's strong management and strategic decisions.

Renovorx Inc

Renovorx Inc Witnesses Decline in Q3 2023 Financial Performance, Sets Path for Recovery

As the earnings season progresses, financial results of various companies are being unveiled. One notable player in the Major Pharmaceutical Preparations sector, Renovorx Inc, recently disclosed its operating loss for the most recent fiscal period ending September 30, 2023. While the figures may seem concerning at first glance, a closer look reveals some interesting developments that could shape the company's future trajectory.
Operating Loss Reduction:
Renovorx Inc reported an operating loss of $-2.983 million for the third quarter of 2023. However, comparing this figure with the same period in 2022, we see a positive trend. In the third quarter of 2022, the operating loss was $-2.161 million, indicating a reduction in losses year-over-year. This demonstrates the company's efforts to streamline operations and improve efficiency, which is essential for its long-term viability.


23andme Holding Co's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com